Category: News & Comments
Interpreting Portola Pharmaceuticals' News
The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not plan to hold an Advisory Committee meeting for its Product betrixaban . What is betrixapan? Betrixapan is a small molecule oral, once-daily, Factor Xa...
Read More
February 9, 2017
0
Inovio Is in Much Better Shape Than Six Months Ago
INOVIO Inovio Pharmaceuticals (INO) is much worth looking at now than 6 months ago. The deal signed between MedImmune, AstraZeneca’s development arm, and Inovio Pharmaceuticals says something. The DEAL MedImmune acquired exclusive rights to Inovio’s INO-3112 immunotherapy against cancers caused...
Read More
August 13, 2015
0
Companies Targeted for Takeover Yet Can Thrive on their Own
It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients allover the globe. Cancer management has unreservedly changed. What seems now to have become...
Read More
February 2, 2017
0
Seattle Genetics Announced Impressive News as Did Celyad
Realizing the dream of approval of a small biotech’s lead drug would usually lead a small development-stage firm to either walking on the road to more achievements and growth, or walking in place doing nothing but spending its revenues while...
Read More
October 4, 2017
0
Kite: News We Are Anxious to Hear
Kite Pharma (Kite) stock was sliding, raising concern about the firm and all the biotech firms that are designing and developing CAR T Cell immunotherapy treatments for cancer. Many investors are wondering about the plummeting of the stock and obviously...
Read More
August 17, 2015
0
Welcoming Jounce Therapeutics (JNCE) as a Public Company
Today, Jounce Therapeutics has begun trading on the NASDAQ under the ticker symbol (JNCE) . The Company, which focuses on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the pricing of its initial public offering of...
Read More
January 22, 2017
0
Seres Therapeutics: A Novel Approach for Treating Clostridium Difficile Infection
but first: Here is some good news from SAREPTA Yesterday we wrote about BioMarin (BMRN) being granted FDA “Rare Pediatric Disease Designation for its Duchenne potential muscular dystrophy (DMD) drug drisapersen. Today, Sarepta Therapeutics (SRPT) also a developer of RNA-targeted...
Read More
August 21, 2015
0
Why Switzerland Approval of Exelixis and Roche Drug Combination for Melanoma Is a Big Deal
- The second approval of a cancer drug for Exelixis - The approval of Exelixis/Roche drugs combination will save lives. - The melanoma the combination drugs treat is a killer with bad prognosis - The terms of Exelixis/Roche agreement are...
Read More
August 27, 2015
0
Vertex and Merck KGaA Agreement Suits Both Firms
Vertex (VRTX) entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four research and development programs that the firm believes represent novel approaches to cancer treatment Merck KGaA will license two clinical-stage...
Read More
January 13, 2017
0
Huge Improvement in the Differential Diagnosis of Diseases and More
The biotechnology industry is proving to be the most innovative and the most growing among Wall Street industries. Individual biotech companies’ achievements complement each other. Some are evolving the sequencing of genes and genetic analysis, while others are excelling in...
Read More
September 2, 2015
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)